Titan Spine Completes 27,000 Endoskeleton Interbody Fusion Device Implantations

Mequon, Wis.-based Titan Spine, a medical device surface surface technology company focused on developing spinal interbody fusion implants, has completed 27,000 implantations of its Endoskeleton interbody fusion devices since its inception—an increase of 25 percent from 2013.

“The significant growth of Titan Spine observed in 2014 alone has been tremendous, and we are extremely well positioned to continue our momentum in 2015 and beyond,” said President Kevin Gemas. “Over the past year, Titan achieved several milestones that attributed to our global growth and further validated our position as the leader in surface technology. These include the expanded use of our devices in Europe, securing market registration approval in Australia and New Zealand, and obtaining U.S. Food and Drug Administration (FDA) clearance for both the Endoskeleton TL, the first lateral device to feature surface technology, as well as our next generation Nanolock surface technology, the first FDA-cleared interbody fusion devices to feature nanotechnology.”

“Not only did 2014 see significant sales growth, but the science of our surface technology is beginning to resonate deeply within the surgeon and scientific communities,” said Steve Cichy, vice president of sales. “Research demonstrating that our devices promote osteoblastic differentiation, while PEEK is actually toxic to osteoblasts and promotes a fibroblastic response, was awarded the prestigious Whitecloud Award for Best Basic Science Research from the Scoliosis Research Society at the International Meeting on Advanced Spine Techniques conference this past July. Recognizing the significance of our surface technology, the industry is ramping up its adoption of our devices and science, and we continue to stand by our commitment of offering quality products for successful spinal surgeries. For this reason, we also began offering a five-year warranty on our full line of spinal implants if a revision surgery is required due to nonunion. We are confident in the science validating our surface technology and look forward to further adoption of our innovative spine devices over this next year and beyond.”

The spine company is planning a full launch of Endoskeleton TL lateral device and an additional unnamed interbody device in the first quarter of this year. Commercialization of Nanolock is planned for the fourth quarter.